Alkahest, Inc. logo

Alkahest, Inc.

Alkahest, Inc. is a biotech company, focus on development of therapies derived from blood to treat neurological diseases, with an emphasis on age-related cognitive decline.

Alkahest was established by Drs. Tony Wyss-Coray and Karoly Nikolich to further develop and commercialize the pioneering work of Dr. Wyss-Coray, and other leading scientists at Stanford University who demonstrated that factors in the blood of young animals were able to restore mental capabilities in old animals.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://www.alkahest.com
Disease Focus
STOCK CODENon Listed
Address
75 Shoreway Road, Suite D, CA 94070
San Carlos
United States
Email
Contact Number
+1 650-801-0474

Alkahest, Inc. is a biotech company, focus on development of therapies derived from blood to treat neurological diseases, with an emphasis on age-related cognitive decline.

Alkahest was established by Drs. Tony Wyss-Coray and Karoly Nikolich to further develop and commercialize the pioneering work of Dr. Wyss-Coray, and other leading scientists at Stanford University who demonstrated that factors in the blood of young animals were able to restore mental capabilities in old animals.

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/alkahest-inc-” connections=”true” suffix=””]

In Mar 2015, Grifols acquires 45% of the equity of Alkahest for $37.5 Mn. Also, in addition Grifols to further provide a payment of $12.5 Mn and fund the development of plasma-based products, which may be commercialized by Grifols throughout the world.

Alkahest acquired ALK4290 from Boehringer-Ingelheim and has exclusive rights for development, commercialization worldwide.

May 2018, Alkahest Receives Grant from Michael J. Fox Foundation; Funding Will Support Preclinical Evaluation of ALK4290 and GRF6019 for Parkinsons Disease.

In Jul 2014, Alkahest, raised $3.50 Mn in series A financing round. In addition to Grifols, Alkahests investors include Bioville Investment Limited, Full House Investment Limited and Stanford University.